Abbott gets clearance for Libre 3 reader, opening path to Medicare coverage

Abbott received Food and Drug Administration clearance for a reader for its newest continuous glucose monitoring (CGM) system.
Its FreeStyle Libre 3 system received clearance in May 2022, but at the time, monitoring could only be done through a smartphone.